Anyone can have lupus, but the fact is that women have more than their fair share of this autoimmune condition. In the U.S., an estimated 1 million to 1.5 million people have
ImmuPharma (LON: IMM) is a United Kingdom domiciled clinical stage therapeutics and Biotechnology company that has interests in the Research and development of novel therapeutics compounds as well as manufacturing
ImmuPharma (LON:IMM | Euronext Growth: ALIMM), a specialist drug discovery and development company, has today announced that, this morning at approximately 09.00am (GMT), ImmuPharma will commence trading on Euronext Growth Brussels under
ImmuPharma (LON:IMM), a specialist drug discovery and development company, today announced that, further to the announcement of 13 December 2019, that its shares will be admitted to trading on Euronext
The Life Sciences Division’s Navid Malik discusses ImmuPharma in this exclusive interview with DirectorsTalk.
ImmuPharma (LON:IMM), a specialist drug discovery and development company, has today announced that its shares will be admitted to trading on Euronext Growth Brussels under ticker ‘ALIMM’ following the approval
Lupus is a medical condition with an aura of mystery. Symptoms affect each patient differently and can mimic other disorders. There’s no single “lupus test” to pinpoint the disease. Lupus is
Life Science Division Executive Director and Head of Research Dr Navid Malik joins DirectorsTalk to discuss ImmuPharma plc (LON: IMM). Navid provides an overview of the Life Science Division and how long its
ImmuPharma (LON:IMM) announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals, a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women
ImmuPharma’s Tim McCarthy discusses their licencing & development agreement with Avion, the Lanstead deal and the key investment points for investing in IMM in this exclusive interview with DirectorsTalk.
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
